Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACTION: Phase 3 Study of Lixivaptan in Autosomal Dominant Polycystic Kidney Disease
2021-003062-12Phase 3Terminated
- Sponsor
- Palladio Biosciences
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in autosomal dominant polycystic kidney disease (ADPKD) comparing Lixivaptan → Open-label lixivaptan with Placebo → Open-label lixivaptan (2 arms). Primary endpoint: Primary endpoint Part 1. Started Oct 2021; status: terminated.
02
Drugs
lixivaptan
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on 2021-003062-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003062-12.